Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like Mallinckrodt Takes Out Sucampo in Surprising $1.2B Deal December 26, 2017 PTC Therapeutics To Host Conference Call To Discuss Second Quarter Financial Results July 24, 2017 FDA Green Lights Gilead's Vosevi, With a Black Box Warning Attached July 18, 2017